Linsitinib achieved a statistically significant proptosis responder rate of 52% vs. 19% for placebo at Week 24 (p=0.010) 82% of Week 24 proptosis responders maintained their response through Week 72 (48 weeks after treatment completion), representing a highly favorable durability…
ANN ARBOR, MI, October 5, 2026 – Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced that data from its Phase 2b/3 LIDS trial of linsitinib…
Linsitinib is the first and only oral IGF-1R inhibitor in Phase 3 development, poised to address multiple TED patient populations Actively enrolling patients ANN ARBOR, MI, September 16, 2026 – Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first…
Commenced global Phase 3 ORBIT pivotal trial evaluating linsitinib in adults with moderate to severe active thyroid eye disease (TED) Linsitinib is the first and only oral small molecule therapy to significantly reduce proptosis in TED, with more convenient dosing…
Lock brings over 20 years of commercial leadership experience as Sling prepares for confirmatory Phase 3 study of linsitinib ANN ARBOR, MI, Jun 18, 2025–(BUSINESS WIRE)–Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule…
Ann Arbor, MI, January 14, 2025 /PR NEWSWIRE/ – Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED.
ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of…
ANN ARBOR, Mich., Jan. 7, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Andrew Guggenhime, an experienced…
ANN ARBOR, Mich., Jan. 6, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced that Raymond Douglas, M.D., Ph.D., Chief Scientific…
Ann Arbor, MI, November 8, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating in three upcoming investor conferences in November…